



ROXABAN DENK

Rivaroxaban

Prescriber Guide

Version 3.0 | April 2026

This educational material is provided to further minimise the risk of bleeding that is associated with the use of rivaroxaban and to guide healthcare professionals in managing that risk.

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals and patients are asked to report any suspected adverse drug reactions via their national reporting system.

Content

Patient Alert Card	4
Prescriber Guide	4
Dosing recommendations	4
Stroke prevention in adult patients with non-valvular atrial fibrillation	4
Patients with renal impairment	4
Duration of therapy	4
Missed dose	4
Patients undergoing percutaneous coronary intervention (PCI) with stent placement	4
Patients undergoing cardioversion	4
Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients and treatment of venous thromboembolism (VTE) and prevention of recurrence in children and adolescents	4
Adults	4
Children and adolescents	5
Patients with renal impairment	5
Duration of therapy	5
Missed dose	5
Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip- or knee-replacement surgery	6
Duration of treatment	6
Missed dose	6
Oral intake	6
Adults	6
Children and adolescents	6
Perioperative management	6
Spinal/epidural anaesthesia or puncture	6
Indication-specific recommendations	6
Converting from Vitamin K Antagonists (VKA) to Roxaban Denk	7
Converting from Roxaban Denk to Vitamin K Antagonists (VKA)	7
Adults	7
Children	7
Converting from parenteral anticoagulants to Roxaban Denk	8
Converting from Roxaban Denk to parenteral anticoagulants	8
Populations potentially at higher risk of bleeding	8
Patients with renal impairment	8
Patients concomitantly receiving other medicinal products	8
Patients with other haemorrhagic risk factors	8
Patients with cancer	9
Other contraindications	9
Overdose	9
Coagulation testing	9
Dosing overview in adults, children and adolescents	10
Abbreviations	11
References	11

Patient Alert Card

A Patient Alert Card is provided to each patient who is prescribed Roxaban Denk with the product package. The implications of anti-coagulant treatment should be explained and the importance of compliance, signs of bleeding and when to seek medical attention discussed with the patient or the caregivers.

The Patient Alert Card will inform physicians and dentists about the patient's anticoagulation treatment and will contain emergency contact information. The patient should be instructed to carry the Patient Alert Card at all times and present it to every healthcare provider.

Prescriber Guide

The Prescriber Guide provides recommendations for the use of Roxaban Denk in order to minimise the risk of bleeding during treatment with Roxaban Denk.

Please note that details of the marketing authorization for rivaroxaban may differ between different countries. Therefore, please see your local Prescribing Information, e.g. the Summary of Product Characteristics (SmPC), for further information and additional details on Roxaban Denk.

The Prescriber Guide does not substitute the Roxaban Denk SmPC. Before prescribing please also read the Roxaban Denk SmPC.

Dosing recommendations

Stroke prevention in adult patients with non-valvular atrial fibrillation

The recommended dose for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA) is 20 mg once daily.

Dosing scheme

Continuous treatment



Roxaban Denk 20 mg once daily*

Take with food

* Recommended dosing scheme for patients with atrial fibrillation and moderate or severe renal impairment see below.

Patients with renal impairment

In patients with moderate (creatinine clearance [CrCl] 30 – 49 mL/min) or severe (CrCl 15 – 29 mL/min) renal impairment the recommended dose is 15 mg once daily. Roxaban Denk is to be used

with caution in patients with severe renal impairment (CrCl 15 – 29 mL/min) and is not recommended in patients with CrCl < 15 mL/min.

Roxaban Denk should be used with caution in patients with renal impairment concomitantly receiving other medicinal products that increase rivaroxaban plasma concentrations.

Duration of therapy

Roxaban Denk should be continued long term provided the benefit of stroke prevention therapy outweighs the potential risk of bleeding.

Missed dose

If a dose is missed, the patient should take Roxaban Denk immediately and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.

Patients undergoing percutaneous coronary intervention (PCI) with stent placement

There is limited experience of a reduced dose of 15 mg rivaroxaban once daily (or 10 mg rivaroxaban once daily for patients with moderate renal impairment [CrCl 30 – 49 mL/min]) in addition to a P2Y12 inhibitor for a maximum of 12 months in patients with non-valvular atrial fibrillation who require oral anticoagulation and undergo PCI with stent placement.

Patients undergoing cardioversion

Roxaban Denk can be initiated or continued in patients who may require cardioversion.


For transesophageal echocardiogram (TEE) guided cardioversion in patients not previously treated with anticoagulants, Roxaban Denk treatment should be started at least 4 hours before cardioversion to ensure adequate anticoagulation. For all patients, confirmation should be sought prior to cardioversion that the patient has taken Roxaban Denk as prescribed. Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account.

Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients and treatment of venous thromboembolism (VTE) and prevention of recurrence in children and adolescents.

Adults

Adult patients are initially treated with Roxaban Denk 15 mg **twice daily** for the first 3 weeks. This initial treatment is followed by Roxaban Denk 20 mg **once daily** for the continued treatment period. When extended prevention of recurrent deep vein thrombosis (DVT) and PE is indicated (following completion of at least 6 months' therapy for DVT or PE), the recommended dose is 10 mg **once daily**. In patients in whom the risk of recurrent DVT or PE is

considered high, such as those with complicated co-morbidities, or who have developed recurrent DVT or PE on extended prevention with Roxaban 10 mg **once daily**, a dose of Roxaban Denk 20 mg **once daily** should be considered.



Children and adolescents

In paediatric patients with a body weight from 30 kg Roxaban Denk treatment should be initiated following ≥ 5 days of initial parenteral anticoagulation treatment. Dosing is based on body weight.

For children and adolescents weighing ≥ 30 kg a Roxaban Denk tablet (15 mg for children 30– < 50 kg, 20 mg for children ≥ 50 kg) can be administered once daily. The dose is determined based on body weight.

For patients with body weight less 30 kg other pharmaceutical forms and strengths might be available.

The weight of a child should be monitored and the dose reviewed regularly. This is to ensure a therapeutic dose is maintained.

Patients with renal impairment

Adults

Patients with moderate (CrCl 30–49 mL/min) or severe (CrCl 15–29 mL/min) renal impairment treated for acute DVT, acute PE and prevention of recurrent DVT and PE should be treated with Roxaban Denk 15 mg twice daily for the first 3 weeks.

Thereafter, the recommended dose is Roxaban Denk 20 mg once daily. A reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient's assessed risk of bleeding outweighs the risk of recurrent DVT and PE. The recommendation for the use of 15 mg is based on pharmacokinetic (PK) modelling and has not been studied in this clinical setting. Roxaban Denk is to be used with caution in patients with severe renal impairment (CrCl 15–29 mL/min) and is not recommended in patients with CrCl < 15 mL/min. When the recommended dose is 10 mg once daily, (after ≥ 6 months of therapy) no dose adjustment from the recommended dose is necessary.

Roxaban Denk should be used with caution in patients with renal impairment¹ concomitantly receiving other medicinal products that increase rivaroxaban plasma concentrations.

Children and adolescents

No dose adjustment is required for children and adolescents with mild renal impairment (glomerular filtration rate: 50 mL–80 mL/min/1.73 m²), based on data in adults and limited data in paediatric patients.

Roxaban is not recommended in children and adolescents with moderate or severe renal impairment (glomerular filtration rate < 50 mL/min/1.73 m²), as no clinical data is available.

Duration of therapy

Adults

Short duration of therapy (≥ 3 months) should be considered in patients with DVT/PE provoked by major transient risk factors (i.e. recent major surgery or trauma). Longer duration of therapy should be considered in patients with provoked DVT/PE not related to major transient risk factors, unprovoked DVT/PE, or a history of recurrent DVT/PE.

Children and adolescents

Therapy with Roxaban Denk should be continued for at least 3 months. Treatment can be extended up to 12 months when clinically necessary. The benefit-risk of continued therapy after 3 months should be assessed on an individual basis taking into account the risk for recurrent thrombosis versus the potential bleeding risk.

Missed dose

Adults

Twice daily treatment period (15 mg twice daily for the first 3 weeks): If a dose is missed, the patient should take Roxaban Denk immediately to ensure intake of 30 mg Roxaban Denk per day. In this case, two 15 mg tablets may be taken at once. Continue with the regular 15 mg twice daily intake on the following day.

Once daily treatment period (beyond 3 weeks): If a dose is missed, the patient should take Roxaban Denk immediately and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.

Children and adolescents

A missed dose should be taken as soon as possible after it is noticed, but only on the same day. If this is not possible, the patient should skip the dose and continue with the next dose as prescribed. The patient should not take two doses to make up for a missed dose.

On the following day, the child/adolescent should continue with the regular once daily regimen.

¹) with moderate renal impairment (CrCl 30–49 mL/min) for Roxaban Denk 10 mg

Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip- or knee-replacement surgery

The recommended dose is 10 mg Roxaban Denk taken orally once daily. The initial dose should be taken 6 to 10 hours after surgery, provided that haemostasis has been established.

Duration of treatment

The duration of treatment depends on the individual risk of the patient for venous thromboembolism which is determined by the type of orthopaedic surgery.

- For patients undergoing major hip surgery, a treatment duration of 5 weeks is recommended
- For patients undergoing major knee surgery, a treatment duration of 2 weeks is recommended

Missed dose

If a dose is missed, the patient should take Roxaban Denk immediately and then continue the following day with once daily intake as before.

Oral intake

Roxaban Denk 10 mg tablets can be taken with or without food. **Roxaban Denk 15 mg and 20 mg tablets are to be taken with food.** The intake of these doses with food at the same time supports the required absorption of the drug, thus ensuring a high oral bioavailability.

Adults

For patients who are unable to swallow whole tablets, a Roxaban Denk tablet may be crushed and mixed with water or apple puree immediately prior to use and then administered orally. After the administration of crushed Roxaban Denk 15 mg or 20 mg film-coated tablets, the dose should be immediately followed by food.

The crushed Roxaban Denk tablet may also be given through gastric tubes after confirmation of the correct gastric placement of the tube. The crushed tablet should be administered in a small amount of water via a gastric tube, after which it should be flushed with water. After the administration of crushed Roxaban Denk 15 mg or 20 mg film-coated tablets, the dose should then be immediately followed by enteral feeding.

Children and adolescents

For patients who are unable to swallow whole tablets, other pharmaceutical forms might be available.

When doses of Roxaban Denk 15 mg or 20 mg are prescribed, these could be provided by crushing the 15 mg or 20 mg tablet and mixing it with water or apple puree immediately prior to use and administered orally.

The crushed Roxaban Denk tablet may be given through nasogastric or gastric feeding tube. Gastric placement of the tube should be confirmed before administering Roxaban Denk. Avoid administration of Roxaban Denk distal to the stomach.

Perioperative management

If an invasive procedure or surgical intervention is required, if possible and based on the clinical judgement of the physician, Roxaban Denk 10/15/20 mg tablets should be stopped at least 24 hours before the intervention.

Roxaban Denk should be restarted after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows, and adequate haemostasis has been established.

Spinal/epidural anaesthesia or puncture

When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with anti-thrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma, which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis.

Indication-specific recommendations

- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation
- Treatment of DVT and PE and prevention of recurrent DVT and PE in adult patients
- Treatment of VTE and prevention of VTE recurrence in children and adolescents

There is no clinical experience with the use of 15 mg and 20 mg rivaroxaban tablets in adults nor with the use of rivaroxaban in children and adolescents in these situations. To reduce the potential risk of bleeding associated with the concurrent use of Roxaban Denk and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is estimated to be low. However, the exact timing to reach a sufficiently

low anticoagulant effect in each patient is not known and should be weighed against the urgency of a diagnostic procedure.

For the removal of an epidural catheter and based on the general pharmacokinetic characteristics at least 2x half-life, i.e. at least 18 hours in young adult patients and 26 hours in elderly patients should elapse after the last administration of Roxaban Denk (see section 5.2 of the SmPC). Following removal of the catheter, at least 6 hours should elapse before the next Roxaban Denk dose is administered. If traumatic puncture occurs, the administration of Roxaban Denk is to be delayed for 24 hours.

No data is available on the timing of placement or removal of a neuraxial catheter in children while on rivaroxaban. Discontinue Roxaban Denk and consider a short acting parenteral anticoagulant.


- Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery

To reduce the potential risk of bleeding associated with the concurrent use of Roxaban Denk and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of Roxaban Denk.

Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of Roxaban Denk is estimated to be low (see section 5.2 of the SmPC).

At least 18 hours should elapse after the last administration of Roxaban Denk before removal of an epidural catheter. Following removal of the catheter, at least 6 hours should elapse before the next Roxaban Denk dose is administered. If traumatic puncture occurs the administration of Roxaban Denk is to be delayed for 24 hours.

Converting from Vitamin K Antagonists (VKA) to Roxaban Denk




For patients treated for **prevention of stroke and systemic embolism**, treatment with VKA should be stopped and Roxaban Denk therapy should be initiated when the **INR ≤ 3.0** .

For adult patients treated for **DVT, PE and prevention of recurrent DVT** and **PE** and treatment of **VTE and prevention of recurrence** in paediatric patients, treatment with VKA should be stopped and Roxaban Denk therapy should be initiated when the **INR ≤ 2.5** .

INR measurement is not appropriate to measure the anticoagulant activity of Roxaban Denk, and therefore should not be used for this purpose. Treatment with Roxaban Denk only does not require routine coagulation monitoring.

Converting from Roxaban Denk to Vitamin K Antagonists (VKA)



It is important to ensure adequate anticoagulation while minimising the risk of bleeding during conversion of therapy.

Adults

When converting to VKA, Roxaban Denk and VKA should be given concurrently until the INR ≥ 2.0 . For the first 2 days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing guided by INR testing.

INR measurement is not appropriate to measure the anticoagulant activity of Roxaban Denk. While patients are on both Roxaban Denk and VKA **the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of Roxaban Denk.** Once Roxaban Denk is discontinued, INR values obtained at least 24 hours after the last dose reliably reflect the VKA dosing.

Children

Children who convert from Roxaban Denk to VKA need to continue Roxaban Denk for 48 hours after the first dose of VKA. After 2 days of co-administration an INR should be obtained prior to the next scheduled dose of Roxaban Denk. Co-administration of Roxaban Denk and VKA is advised to continue until the INR is ≥ 2.0 . Once Roxaban Denk is discontinued, INR values obtained at least 24 hours after the last dose reliably reflect the VKA dosing.

Converting from parenteral anticoagulants to Roxaban Denk

- Patients with a parenteral drug on a fixed dosing scheme such as low-molecular-weight heparin (LMWH): Discontinue parenteral drug and start Roxaban Denk 0 to 2 hours before the time of the next scheduled administration of the parenteral drug
- Patients with a continuously administered parenteral drug such as intravenous unfractionated heparin: Start Roxaban Denk at the time of discontinuation

Converting from Roxaban Denk to parenteral anticoagulants

Give the first dose of the parenteral anticoagulant at the time the next Roxaban Denk dose would be taken.

Populations potentially at higher risk of bleeding

Like all anticoagulants, Roxaban Denk may increase the risk of bleeding. Therefore, Roxaban Denk is contraindicated in patients:

- With clinically significant active bleeding
- With a lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
- Receiving concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), LMWHs (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under the circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter.
- With hepatic disease associated with coagulopathy and clinically relevant bleeding risk including Child-Pugh class B and C cirrhotic patients.

Elderly population: The risk of bleeding increases with increasing age.

Several sub-groups of patients are at increased risk of bleeding and should be carefully monitored for signs and symptoms of bleeding complications.

Treatment decision in these patients should be carried out after assessment of treatment benefit against the risk for bleeding.

Patients with renal impairment

For adults see dosing recommendations for patients with moderate (CrCl 30 – 49 mL/min) or severe (CrCl 15 – 29 mL/min) renal impairment. Roxaban Denk is to be used with caution in patients with CrCl 15 – 29 mL/min and in patients with renal impairment¹ concomitantly receiving other medicinal products, that increase rivaroxaban plasma concentrations. Use of Roxaban Denk is not recommended in patients with CrCl < 15 mL/min.

In children no dose adjustment is required with mild renal impairment (glomerular filtration rate: 50 – 80 mL/min/1.73 m²). Roxaban Denk is not recommended in children with moderate or severe renal impairment (glomerular filtration rate < 50 mL/min/1.73 m²).

Patients concomitantly receiving other medicinal products

- Systemic azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir): use of Roxaban Denk is not recommended
- Care is to be taken in patients concomitantly receiving drugs affecting haemostasis such as non-steroidal anti-inflammatory drugs, acetylsalicylic acid (ASA), platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs)
- The interaction with erythromycin, clarithromycin or fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-risk patients (for patients with renal impairment see further above)

Interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known. The warnings above should be taken into account for the paediatric population.

Patients with other haemorrhagic risk factors

As with other antithrombotics, Roxaban Denk is not recommended in patients with an increased bleeding risk such as:

- Congenital or acquired bleeding disorders
- Uncontrolled severe arterial hypertension
- Other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)
- Vascular retinopathy
- Bronchiectasis or history of pulmonary bleeding

¹) with moderate renal impairment (CrCl 30 – 49 mL/min) for Roxaban Denk 10 mg

Patients with cancer

Patients with malignant disease may simultaneously be at higher risk of bleeding and thrombosis. The individual benefit of antithrombotic treatment should be weighed against risk for bleeding in patients with active cancer dependent on tumour location, anti-neoplastic therapy and stage of disease. Tumours located in the gastrointestinal or genitourinary tract have been associated with an increased risk of bleeding during Roxaban Denk therapy.

In patients with malignant neoplasms at high risk of bleeding, the use of Roxaban Denk is contraindicated.

Other contraindications

Roxaban Denk is contraindicated during pregnancy and breastfeeding. Women of child-bearing potential should avoid becoming pregnant during treatment with Roxaban Denk. Roxaban Denk is also contraindicated in case of hypersensitivity to the active substance or to any of the excipients.

Overdose

Due to limited absorption, a ceiling effect with no further increase in average plasma exposure is expected at supratherapeutic doses of 50 mg rivaroxaban and above in adults; however, no data is available at supratherapeutic doses in children. A decrease in the relative bioavailability for increasing doses (in mg/kg body-weight) was found in children, suggesting absorption limitations for higher doses, even when taken together with food.

For situations when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, a reversal agent for factor Xa inhibitors is available. However, it is not established in children. The reversal agent may not be available in every country. The use of activated charcoal to reduce absorption in case of overdose may be considered.

Should a bleeding complication arise in a patient receiving Roxaban Denk, the next Roxaban Denk administration should be delayed or treatment should be discontinued as appropriate. Individualised bleeding management may include:

- Symptomatic treatment, such as mechanical compression, surgical intervention, fluid replacement
- Haemodynamic support, blood product or component transfusion
- If bleeding cannot be controlled with the above measures, either the administration of a specific factor Xa inhibitor reversal agent (andexanet alfa) or a specific procoagulant reversal agent, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa) should be considered. However, there is currently very limited clinical experience with the use of these medicinal products in adults and in children receiving rivaroxaban.

Due to the high plasma protein binding, rivaroxaban is not expected to be dialyzable.

Coagulation testing

Roxaban Denk does not require routine coagulation monitoring. However, measuring rivaroxaban levels may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to take clinical decisions, e.g. overdose and emergency surgery.

Anti-FXa assays with rivaroxaban specific calibrators to measure rivaroxaban levels are commercially available. If clinically indicated haemostatic status can also be assessed by prothrombin time (PT) using Neoplastin as described in the SmPC.

The following coagulation tests are increased: PT, activated partial thromboplastin time (aPTT) and calculated PT INR. Since the INR was developed to assess the effects of VKAs on the PT, it is therefore not appropriate to use the INR to measure activity of rivaroxaban.

Dosing or treatment decisions should not be based on results of INR except when converting from Roxaban Denk to VKA as described above.

Dosing overview in adults, children and adolescents

Indication ¹	Dosing ¹	Special populations ¹
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation*	Roxaban Denk 20 mg once daily	In patients with impaired renal function with CrCl 15 – 49 mL/min** Roxaban Denk 15 mg once daily PCI with stent placement For a maximum of 12 months Roxaban Denk 15 mg once daily plus a P2Y ₁₂ inhibitor (e.g. clopidogrel) PCI with stent placement in patients with impaired renal function with CrCl 30 – 49 mL/min** Roxaban Denk 10 mg once daily plus a P2Y ₁₂ inhibitor (e.g. clopidogrel)
Treatment of DVT and PE*** , and prevention of recurrent DVT and PE in adult patients	Treatment and prevention of recurrence, day 1 – 21 Roxaban Denk 15 mg twice daily Prevention of recurrence, from day 22 onwards Roxaban Denk 20 mg once daily Extended prevention of recurrence, from month 7 onwards Roxaban Denk 10 mg once daily Extended prevention of recurrence, from month 7 onwards Roxaban Denk 20 mg once daily in patients at high risk of recurrent DVT or PE, such as those: • with complicated comorbidities • who have developed recurrent DVT or PE on extended prevention with Roxaban Denk 10 mg	In patients with impaired renal function with CrCl 15 – 49 mL/min** Treatment and prevention of recurrence, day 1 – 21 Roxaban Denk 15 mg twice daily Thereafter Roxaban Denk 15 mg once daily instead of Roxaban Denk 20 mg once daily if patient's assessed risk for bleeding outweighs risk for recurrence When the recommended dose is Roxaban Denk 10 mg once daily, no dose adjustment is necessary
Treatment of VTE and prevention of VTE recurrence in children and adolescents	Initiated following at least 5 days of initial parenteral anticoagulation treatment: • Body weight from 30 kg to 50 kg: Roxaban Denk 15 mg once daily • Body weight ≥ 50 kg: Roxaban Denk 20 mg once daily	In patients with mild impaired renal function with glomerular filtration rate 50 – 80 mL/min/1.73 m ²): no dose adjustment is required. Children and adolescents with moderate or severe renal impairment with glomerular filtration rate < 50 mL/min/1.73 m ²): Roxaban Denk is not recommended.
Prevention of VTE in adults undergoing elective hip or knee replacement surgery	Roxaban Denk 10 mg once daily	–

Roxaban Denk 15 mg and 20 mg must be taken with food¹

For patients who are unable to swallow whole tablets, Roxaban Denk tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally.

* With one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

** Use with caution in patients with creatinine clearance 15 – 29 mL/min and in patients with renal impairment when concomitantly receiving other medicinal products that increase rivaroxaban plasma concentration.

*** Not recommended as an alternative to unfractionated heparin in patients with PE who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy.

Abbreviations

CrCl	creatinine clearance
DVT	deep vein thrombosis
HIV	human immunodeficiency virus
INR	international normalised ratio
LMWH	low-molecular-weight heparin
PCI	percutaneous coronary intervention
PE	pulmonary embolism
SmPC	Summary of Product Characteristics
VKA	vitamin K antagonist
VTE	venous thromboembolism
UFH	unfractionated heparin

References

[1] Roxaban Denk (rivaroxaban). Summary of Product Characteristics



Scan for digital version



denkpharma.com/educational-material